EMPOWER-Lung 1: A Randomized, Open-Label, Multi-National, Phase III Trial of Cemiplimab, A Human PD-1 Monoclonal Antibody, Versus Chemotherapy In First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With PD-L1 >= 50%

Simple item page
dc.contributor.authorSriuranpong, V.
dc.contributor.authorAltundag, O.
dc.contributor.authorClingan, P.
dc.contributor.authorRizvi, N.
dc.contributor.authorFrontera, O. Aren
dc.contributor.authorSezer, A.
dc.contributor.authorPaydas, S.
dc.contributor.authorShavdia, M.
dc.contributor.authorBondarenko, I.
dc.contributor.authorGladkov, O.
dc.contributor.orcID0000-0003-0197-6622en_US
dc.contributor.orcID0000-0003-4642-3693en_US
dc.contributor.researcherIDW-9219-2019en_US
dc.contributor.researcherIDF-3132-2018en_US
dc.date.accessioned2023-04-18T10:55:01Z
dc.date.available2023-04-18T10:55:01Z
dc.date.issued2018
dc.identifier.issn0923-7534en_US
dc.identifier.issueSupplement 10en_US
dc.identifier.urihttp://hdl.handle.net/11727/8819
dc.identifier.volume29en_US
dc.identifier.wos000459294800115en_US
dc.language.isoengen_US
dc.relation.journalANNALS OF ONCOLOGYen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleEMPOWER-Lung 1: A Randomized, Open-Label, Multi-National, Phase III Trial of Cemiplimab, A Human PD-1 Monoclonal Antibody, Versus Chemotherapy In First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With PD-L1 >= 50%en_US
dc.typeConference Objecten_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Tıp Fakültesi / Faculty of Medicine